SUPPLEMENTAL AGREEMENT TO SHARE TRANSFER CONTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS CO., LTD. AND FORMER SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.
Exhibit 10.1
[Unofficial Translation]
SUPPLEMENTAL AGREEMENT TO
SHARE TRANSFER CONTRACT
OF
SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.
BY AND BETWEEN
SHAANXI AOXING PHARMACEUTICALS CO., LTD.
AND
FORMER SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.
Supplemental Agreement
Party A: Shaanxi Aoxing Pharmaceuticals Co., Ltd. (hereinafter referred to as “Transferee”)
Party B: All Former Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. who are listed in Appendix I of this Agreement (hereinafter referred to as “Transferors”)
Transferors and Transferee are hereinafter collectively referred to as “Parties” and each referred to as a “Party”.
WHEREAS,
(1)The Parties signed a Framework Agreement on the acquisition of Party B’S 100% equity interests of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. (“Huaren Pharmaceuticals”) on December 27, 2010, as well as a Share Transfer Contract on October 11, 2011.
(2)Transferors own the 13 Reregistered Drug Approval Numbers of Huaren Pharmaceuticals. Transferors have the right to exercise all of their rights as an intellectual property holder.
(3) The Transferors has transferred all (100%) equity interests of Huaren Pharmaceuticals except the 13 Reregistered Drug Approval Numbers to the Transferee. The Share Transfer Contract signed by the Parties on October 11, 2011 has been fully performed.
(4) The Transferee is willing to purchase the 13 Reregistered Drug Approval Numbers of Huaren Pharmaceuticals held by the Transferors under the terms and conditions of this Agreement.
THEREFORE, in principle of equality and mutual benefits, through friendly negotiation, Parties hereto agree to enter into, in accordance with Company Law of People’s Republic of China (the “PRC”), Contract Law of the PRC and other applicable PRC laws and regulations, the following agreement.
I Transfer Target
The 13 Registered Drug Approval Numbers include but not limited to Jingang Tablet owned by the Transferors as set forth Appendix III.
II Transfer Price
Transferors and Transferees after full negotiation have finally agreed that the transfer price for the 13 Reregistered Drug Approval Numbers shall be RMB 66,000,000 (hereinafter referred to as “Transfer Price”), of which RMB 55,000,000 should be paid in cash, and the remaining RMB 11,000,000 shall be paid in 1,602,564 shares of common stock of Biostar Pharmaceuticals, Inc. (“BSPM”), which are valued by the Parties at $1.10 per share (Issuance Price), using a USD to RMB exchange rate of 6.24:1.
III Payment of the Transfer Price
1. The Parties hereby confirm that the Transferee delivered RMB 30,000,000 as deposit payment to Transferors on November 26, 2012.
2. Upon the request of the Transferors, the Transferee paid the Transferors RMB 25,000,000 on December 31, 2012, while the BSPM common stock shall be paid when the following terms and conditions are met.
(1) The Transferors have completed the registration for the 13 drugs in Appendix III with Shanxi Province Food and Drug Administration Bureau;
(2) All the records and product registration materials have been delivered to the Transferee;
(3) The Transferors shall pay the personal income tax for the full Purchase Price in accordance with the laws and regulations of the PRC as well as provide the Transferee with personal income tax clearance certificates issued by the relevant tax authorities within two months after the signing of this Agreement;
(4) To fulfill other obligations required by the Transferee within two months after signing of the Agreement.
IV The Conditions of Payment of Transfer Price and Closing
1. According to this Agreement, the payment of RMB25, 000,000 to the Transferors by the Transferee is conditioned on the fulfillment of Section 2 (1) of Article III.
2. The Transferors and the Transferee hereby reconfirm that the delivery of the stock payment shall be conditioned upon the issuance of a written confirmation letter by the Transferee, before which, the Transferors shall not be deemed to have paid the balance of the Purchase Price.
3. The Parties agree to complete the handover of original materials for the Reregistered Approval Numbers in five business days after execution of this Agreement. The date on which the handover is completed shall be the closing date.
V Terms of Payment
1. The Transferee has transferred fund to the bank accounts designated by the Transferors according to the terms agreed by all the Parties before signing the Agreement.
2. BPSM common stock shall be delivered after the fulfillment of Section 2 of Article III.
3. The Transferors shall deliver to the Transferee the lawful receipt of the payment within three business days upon receipt of the payment by the Transferee.
VI Tax
Any taxes or fees arising out of the performance of the terms of this Agreement by each of Transferors and Transferee shall be payable by the respective Party liable for the taxes or fees under the provisions of relevant laws and regulations of the PRC.
VII Special Provisions
(1) Within six months after the signing date of this Agreement, none of the Transferors shall sell, transfer or pledge any of the BSPM common stock transferred to him/her by the Transferee to any individual or entities other than to the Transferee or another party permitted or designated by the Transferee; After six months, if any of the Transferors intends to sell, transfer or pledge the BSPM common stock held by such Transferor, the Transferee or its permitted or designated party has the right of first refusal to purchase such shares. The terms and conditions of the purchase specified in this provision shall be governed by Section (3) below of this Article VII.
(2) If fund is available, the Transferee shall have the right to purchase or to permit or designate a third party to purchase all or part of the transferred BSPM common stock from the Transferors within two months after issuance of the BSPM common stock. The Transferors hereby consent to the purchase by the Transferee or its designated or permitted party. The terms and conditions of the purchase specified in this provision shall be governed by Section (3) below of this Article VII.
(3) In the event that the Transferee chooses to purchase or to permit or designate a third party to purchase the BSPM common stock from the Transferors, the Transferee or its permitted or designated party shall have the right to purchase such BSPM common stock in a lump sum at a premium of 15% of the BSPM common stock Issuance Price (i.e., $1.10 per share). Once the purchase is completed, the Transferors shall not impose any other conditions or considerations of the transfer for any reason (including raising any claims or initiating any lawsuit) on the Transferee or the third party designated or permitted by the Transferee and the Transferors shall waive any claim or right to claim for damage or right to litigate.
VIII Share Transfer Contract
1. The Share Transfer Contract signed on October 11,2011 by the Parties have been fully performed. The Registered Drug Approval Numbers referred to in this Agreement is the intellectual property of the Transferors. The re-registration of these 13 drugs has been not completed at the time of the share transfer, therefore the 13 drugs were excluded from the Share Transfer Contract. The signing and performance of this Agreement supplements the Framework Agreement and Share Transfer Contract and helps integrate the equity and assets of the Company.
2. The Parties agree that the representations, warranties and disclosure by both Parties in the Share Transfer Contract and the Framework Agreement are truthful and valid, which are also applicable to this Agreement.
IX Breach of Contract
1. If the breach of representation or warranty by any Party results in the economic loss of the other Party, the breaching party shall be responsible for the full damage.
2. In the event of a breach committed by any Party to this Agreement, the said breaching Party shall be liable to the other Party for any liabilities arising out of that the breaching Party’s breach of contract in accordance with the Share Transfer Contract and the Framework Agreement. In case of breach of the Agreement by all Parties hereto, a Party shall respectively assume liabilities for any loss or damage, or any other liabilities, arising out of its breach of Contract, against other Parties.
X Dispute Resolution
Any dispute arising out of this Agreement between the Parties t shall firstly be resolved through friendly negotiation. In the event that the dispute cannot be resolved through such means, either Party may submit the dispute to Xianyang municipal intermediate people's court or apply for arbitration to XianYang municipal arbitration commission.
XI Miscellaneous
1. Non-Waiver: The non-exercise or delay in the exercise of any rights provided for in this Agreement by any Party to this Agreement shall not be regarded as a waiver of the said entitlement. Any single exercise or partial exercise of any right shall not rule out any future re-exercise of the said right.
2. Transfer: Unless otherwise prescribed in this Agreement, neither Party to this Agreement shall transfer or assign all or any part of such Party’s rights or obligations in this Agreement without the prior written consent from the other Parties.
3. Amendment: This Agreement has been executed for the benefits of all Parties to this Agreement and their respective lawful successor(s) and assignees, and shall have legal binding effect on them. Any amendment to this Agreement must be in writing. Only a written document signed by all Parties indicating their consent to such amendment shall be as effective as the original agreement.
4. The validity of text and appendix
(1) The Agreement shall be effective upon the execution of the Agreement by the Parties hereof. The Agreement shall be written in ten original copies, with the Transferors holding seven original copies, the Transferee holding one, and the remaining two copies shall be kept by Huaren Pharmaceuticals.
(2) Appendixes are integral parts of this Agreement, and shall have the same effect with this Agreement.
(3) This Chinese version of this Agreement is the only valid and binding version. The English translation is only for reference purposes.
IN WITNESS WHEREOF, the duly authorized representative of Party A and Party B have signed this Agreement on the date first above written.
Party A: Shaanxi Aoxing Pharmaceuticals Co., Ltd.
(Seal)
Authorized Representative (Signature):
Party B: All Former Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd.
Signatures:
Appendix I
Former Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd.
1. Jian’▇▇▇ ▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding 30% equity interests of Huaren；
2. ▇▇▇ ▇▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding 21% equity interests of Huaren；
3. ▇▇▇▇▇▇ ▇▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding10% equity interests of Huaren；
4. ▇▇▇▇▇ ▇▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding 10% equity interests of Huaren；
5. ▇▇▇▇ ▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding 10% equity interests of Huaren；
6. ▇▇▇▇ ▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding 9.5% equity interests of Huaren；and
7. Biao Ning，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，previously holding 9.5% equity interests of Huaren.
Appendix II
SHARE TRANSFER CONTRACT
OF
SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.
BY AND BETWEEN
SHAANXI AOXING PHARMACEUTICALS CO., LTD.
AND
SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.
INDEX
|
CHAPTER I
|
DEFINITION AND INTERPRETATION
|
|
|
ARTICLE 1
|
DEFINITION
|
|
|
CHAPTER II
|
TRANSFERRED SHARES
|
|
|
ARTICLE 2
|
SHARE TRANSFER
|
|
|
ARTICLE 3
|
TRANSFER PRICE
|
|
|
ARTICLE 4
|
CONDITIONS FOR THE PAYMENT OF THE TRANSFER PRICE AND CLOSING
|
|
|
ARTICLE 5
|
PAYMENT
|
|
|
ARTICLE 6
|
TAX PAYABLE
|
|
|
ARTICLE 7
|
DRUG AND HEALTH PRODUCTS APPROVAL NUMBERS
|
|
|
CHAPTER III
|
REPRESENTATIONS AND WARRANTIES BY ALL PARTIES
|
|
|
ARTICLE 8
|
REPRESENTATIONS AND WARRANTIES BY ALL PARTIES
|
|
|
CHAPTER IV
|
DISCLOSURES, REPRESENTATIONS AND WARRANTIES BY THE TRANSFERORS
|
|
|
ARTICLE 9
|
DISCLOSURES, REPRESENTATIONS AND WARRANTIES BY THE TRANSFERORS
|
|
|
ARTICLE 10
|
GENERAL REPRESENTATIONS AND WARRANTIES BY TRANSFERORS
|
|
|
ARTICLE 11
|
OWNERSHIP
|
|
|
ARTICLE 12
|
SPECIAL REPRESENTATIONS AND WARRANTIES BY THE TRANSFERORS
|
|
|
CHAPTER V
|
DISCLOSURES, REPRESENTATIONS AND WARRANTIES OF TRANSFEREE
|
|
|
ARTICLE 13
|
DISCLOSURES, REPRESENTATIONS AND WARRANTIES OF THE TRANSFEREE
|
|
|
CHAPTER VI
|
EMPLOYEES
|
|
|
ARTICLE 14
|
EMPLOYEES
|
|
|
CHAPTER VII
|
CONFIDENTIALITY
|
|
|
ARTICLE 15
|
CONFIDENTIALITY
|
|
|
CHAPTER VIII
|
BREACH OF CONTRACT
|
|
|
ARTICLE 16
|
LIABILITIES FOR VIOLATION OF REPRESENTATIONS OR WARRANTIES
|
|
|
ARTICLE 17
|
LIABILITIES FOR BREACH OF CONTRACT
|
|
|
CHAPTER IX
|
FORCE MAJEURE
|
|
|
ARTICLE 18
|
FORCE MAJEURE
|
|
|
CHAPTER X
|
RESOLUTION OF DISPUTES
|
|
|
ARTICLE 19
|
ARBITRATION
|
|
|
ARTICLE 20
|
VALIDITY OF ARBITRAL AWARD
|
|
|
ARTICLE 21
|
CONTINUATION OF RIGHTS AND OBLIGATIONS
|
|
|
CHAPTER XI
|
APPLICABLE LAW
|
|
|
ARTICLE 22
|
APPLICABLE LAW
|
|
|
CHAPTER XII
|
MISCELLANEOUS
|
|
|
ARTICLE 23
|
NON-WAIVER
|
|
|
ARTICLE 24
|
TRANSFER
|
|
|
ARTICLE 25
|
AMENDMENT
|
|
|
ARTICLE 26
|
SEVERABILITY
|
|
|
ARTICLE 27
|
LANGUAGE
|
|
|
ARTICLE 28
|
EFFECTIVENESS OF TEXT AND APPENDIXES
|
|
|
ARTICLE 29
|
NOTIFICATION
|
|
|
ARTICLE 30
|
ENTIRE AGREEMENT
|
|
|
APPENDIX I SHAREHOLDERS OF HUAREN
|
||
|
APPENDIX II PRE-REQUISITE CONDITIONS
|
||
|
APPENDIX III DRUG AND HEALTH PRODUCT APPROVAL NUMBERS
|
||
|
APPENDIX IV DRUG APPROVAL NUMBERS FOR RE-REGISTRATION APPLICATION
|
||
Share Transfer Contract
This Share Transfer Contract (hereinafter referred to as the “Contract”) is entered into by and between the following Parties in Xianyang, China on October 11, 2011:
|
(1)
|
Party A: Shaanxi Aoxing Pharmaceuticals Co., Ltd. (hereinafter referred to as “Transferee”)，a company incorporated under PRC law；
|
|
(2)
|
Party B: Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. as specified in Appendix I of this Contract (hereinafter referred to as “Transferors”).
|
Transferors and Transferee are hereinafter collectively as “Parties” and individually referred to as a “Party”.
WHEREAS,
|
(1)
|
The Transferors hold 100% equity interests of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. (hereinafter referred to as “Huaren”). The Transferors can exercise all of its full rights as the shareholders of Huaren;
|
|
(2)
|
The Transferors agree to transfer all (100%) equity interests they collectively hold of Huaren to the Transferee in accordance with terms and conditions as stipulated hereunder (hereinafter referred to as “Transferred Shares”) ;
|
|
(3)
|
The Transferee agrees to accept the transfer of all (100%) equity interests held by Transferors of Huaren in accordance with the terms and conditions as stipulated hereunder.
|
THEREFORE, in principle of equality and mutual benefits, through friendly negotiation, Parties hereto agree to reach, in accordance with Company Law of the People’s Republic of China, Contract Law of the People’s Republic of China and other applicable PRC laws and regulations, the following agreement.
Chapter I Definition and Interpretation
|
Article 1
|
Definition
|
Unless otherwise prescribed and stipulated, the following terms used in this Contract shall have the meanings set forth as follows:
“Huaren” refers to Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd., a limited liability company incorporated under PRC law, with registered capital (paid-in capital) amounted to RMB 6,200,000, registration number of its legal and valid business license 610502100009599, registered at ▇▇.▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇.
“PRC” refers to, for purpose of the Contract, People’s Republic of China, excluding Hong Kong, Taiwan and Macau.
“Claim” means claims, actions, demands, proceedings judgments liabilities, damages amounts, costs and expenses (including all lawyers fees, legal costs and disbursements) whatsoever and howsoever arising.
“Signing Date” means the date on which this Contract is signed.
“Encumbrance” means any mortgage, assignment, lien, charge, pledge, title retention, right to acquire, security interest, option, pre-emptive right, and any other restriction or conditions whatsoever including:
(i) any interest or right granted or reserved in or over or affecting the Transferred Shares for Transfer; or
(ii) the interest or right created or otherwise arising in or over the Transferred Shares for Transfer under a fiduciary transfer, charge, lien, pledge, power of attorney or other form of encumbrance; or
(iii) any security over the Transferred Shares for transfer for the payment of a debt or any other monetary obligation or the performance of any other obligation.
“Material Adverse Change” refers to (1) Any investigation (would likely cause Huaren subject to an administrative punishment) or punishment on Huaren by governmental authorities; (2) Any suit, arbitration or any other judicial proceedings involving Huaren; (3) Any change would cause or reasonably may cause material adverse effect on the finance, business, properties, liabilities or operation results of Huaren or the prospect thereof.
“RMB” means the lawful currency of PRC.
“Third Party” means any natural person, legal person, other organization or entity, other than Parties hereto.
“Business Day” refers to any day on which all banks in Shaanxi are open for business.
Chapter II Transferred Shares
|
Article 2
|
Share Transfer
|
Pursuant to the terms stipulated in this Contract, the Transferors hereby agree to transfer to Transferee and Transferee agrees to accept from Transferors the Transferred Shares being one hundred percent (100%) of the equity interests of Huaren (namely, all capital contributions of Huaren) with all the rights and obligations attaching to the Transferred Shares for transfer including, but not limited to, general rights thereof, all the rights to receive dividends and to receive or subscribe for shares (if any) declared, paid or issued by Huaren (if any), and free of any Claim or Encumbrance.
|
Article 3
|
Transfer Price
|
3.1 The Transferors and the Transferee after consultations have finally determined that the Transfer Price for the transfer of the Transferred Shares shall be RMB 61,000,000 (hereinafter referred to as “Transfer Price”);
3.2 Payment Term
3.2.1 The Parties hereby confirm that Transferee delivered RMB 30,000,000 as deposit to the Transferors on December 29, 2010 (hereinafter referred to as “Deposit”);
3.2.2 The Transferee shall pay RMB 15,000,000 to the Transferors within three (3) business days as of the Closing Date (as defined in Article 4.4). The balance, RMB 16,000,000, shall be paid after the following conditions are met: 1) the Transferors meet all pre-requisite conditions set out in Appendix II of this Contract (hereinafter referred to as “Pre-requisite Conditions”), 2) the Transferors pay the individual income tax regarding the Transferred Shares (hereinafter referred to as “Individual Income Tax”) in full according to PRC laws and regulations, and provide tax clearance certificates of Individual Income Tax issued by relevant tax authority within two(2) months as of the Signing Date, 3) the Transferors perform other duties required by the Transferee which are required to be fulfilled within two (2) months as of the Signing Date, and 4) Huaren is free of any material adverse change from the Signing Date to Final Payment Date (as defined in Article 5.1) (hereinafter collectively referred to as “Balance Payment Conditions”).
|
Article 4
|
Conditions for the Payment of the Transfer Price and Closing
|
4.1Under this Contract, the condition for the payment of RMB 15,000,000 is the satisfaction of Article 4.4. The conditions for the payment of the balance, RMB 16,000,000, are the satisfaction of the Balance Payment Conditions as stipulated in Article 3.2.2.
4.2 The Parties hereby confirm that the satisfaction of the Balance Payment Conditions shall be subject to the written confirmation by the Transferee. The Balance Payment Conditions shall not be deemed as having been satisfied until the Transferors obtain the written confirmation issued by the Transferee.
4.3 In the event that any of the conditions set out in Article 4.1 have not been satisfied or implemented, and Transferee has not indicated its waiver of the said conditions or any one of them, in writing, Transferee shall not be obliged to pay the Transfer Price to Transferors.
4.4 The Transferors and the Transferee hereby agree that the closing date shall be the date on which Huaren completes the share transfer registration with the Administration for Industry and Commerce where Huaren is registered (hereinafter referred to as “AIC”) within fifteen (15) business days as of the Signing Date, and the Transferee becomes the sole registered shareholder of Huaren (hereinafter referred to as “Closing Date”).
|
Article 5
|
Payment
|
5.1 The Transferee shall pay RMB 15,000,000 to the bank account(s) designated by the Transferors within three (3) business days as of the Closing Date. The payment of the balance, RMB 16,000,000, shall be subject to Article 3.2.2. The payment date shall be the date when the Transferee pays RMB 15,000,000 to the Transferors (hereinafter referred to as “Payment Date”). The final payment date shall be the date when the balance RMB 16,000,000 is paid to the Transferors (hereinafter referred to as “Final Payment Date”).
5.2 The Transferors shall issue to Transferee the evidential document of the payment received within two (2) business days.
5.3 Within three (3) business days from the Closing Date, the Transferors shall hand over all materials to the Transferee or the representative designated by the Transferee, or the Transferors shall require relevant institutions or persons to transfer all materials of Huaren includes, but not limited to the official seal, financial seal, contract seal, account information, all accounting voucher, account book (including but not limited to personal seal and signature pre-submitted by Huaren to the bank changed to the personal seal and signature of the person designated by the Transferee), all official documents, licenses, permissions and client information relating to the business of Huaren, all contracts and agreements signed by Huaren, staff information, technical data and other relevant materials, and to take any measures to ensure the Transferee to control properties and business operation of Huaren.
|
Article 6
|
Tax Payable
|
| Any taxes or fees arising out of and payable pursuant to the fulfillment of the terms of this Contract by each of Transferors and Transferee shall be payable by the respective Party liable for the taxes or fees under the provisions of relevant PRC laws and regulations. |
|
Article 7
|
Drug and Health Products Approval Numbers
|
| The Transferors shall transfer eighty-six (86) drug approval numbers and one (1) health products approval number set out in Appendix III to the Transferee (hereinafter referred to as “Approval Numbers”); the Transferors shall conduct re-registration application regarding the thirteen (13) drug approval numbers set out in Appendix IV (hereinafter referred to as “Re-registration Approval Numbers”) to competent authorities, and any fees arising from the application of Re-registration Approval Numbers shall be paid by the Transferors. Without the prior written consent of the Transferors, the Transferee cannot use the Re-registration Approval Numbers after the Closing Date. |
Chapter III Representations and Warranties by All Parties
|
Article 8
|
Representations and Warranties by All Parties
|
8.1 The Transferors and the Transferee confirm that this Contract shall be a document having legal binding effect on all Parties from the Signing Date.
8.2 At the time of signing this Contract, Transferors and the Transferee state that the documents and information provided to any other Party or their agencies (including without limitation to the lawyers, appraisers, financial consultants, etc.) prior to the Signing Date shall remain effective，and confirm that where there are discrepancies therein with the terms of this Contract, this Contract shall prevail.
8.3 The Transferors and the Transferee hereby agree that the contracts or documents pertaining to Transferred Shares entered into between all Parties prior to this Contract shall lapse automatically upon this Contract coming into effect.
8.4 Unless otherwise provided in this Contract, all rights and obligations enjoyed or assumed previously by the Transferors over Transferred Shares shall be entirely transferred to the Transferee after the Closing date.
8.5 All Parties to this Contract agree to strive jointly in coordinating the work pertaining to the transfer of the Transferred Shares, including but not limited to registration and filing of record, etc., and the expenses arising therefrom shall be borne by Huaren.
8.6 The board of directors of Huaren after the Closing Date (hereinafter referred to as “Board”) shall be composed of three directors who are all appointed by the Transferee. The Chief Financial Officer of Huaren shall also be appointed by the Transferee.
Chapter IV Disclosures, Representations and Warranties by the Transferors
|
Article 9
|
Disclosures, Representations and Warranties by the Transferors
|
The Transferors hereby jointly represent and warrant to the Transferee that:
9.1 All information and facts relating to Huaren that is in the possession of the Transferors or is known to any of the Transferors which will have a substantive and adverse effect on Transferors’ ability to fulfill any of its obligations in this Contract or when disclosed to Transferee shall have a substantive effect on the willingness of Transferee to sign and fulfill its obligations under this Contract, have been disclosed to Transferee and the information provided by Transferors to Transferee does not contain any representation that is untrue or misleading.
9.2 No lawsuits, arbitrations, or other legal or administrative proceedings or governmental investigations are on-going against the Transferors that will materially affect its ability to sign this Contract or fulfill its obligations under this Contract.
9.3Regarding the documents and information provided by the Transferors to the Transferee and/or the Transferee’s agencies (including without limitation to the lawyers, appraisers, financial consultants, etc.) prior to the Signing Date, the Transferors hereby jointly undertake that:
|
9.3.1
|
all copies made from original documents are true and complete;
|
|
9.3.2
|
all original documents are authentic and complete;
|
|
9.3.3
|
all documents supplied to the Transferee and/or the Transferee’s agencies as originals are authentic and complete;
|
|
9.3.4
|
all signatures appearing on documents supplied to Transferee and/or Transferee’s agencies as originals or copies of originals are genuine; and
|
|
9.3.5
|
Transferors have drawn to the attention of Transferee and/or Transferee’s agencies all matters that are material for Transferee to proceed with the transaction as contemplated in this Contract.
|
9.4 The Transferors agree to sign Non-Competition Agreements with Huaren and to ensure that the major management personnel and technical personnel of Huaren would sign Non-Competition Agreements with Huaren, which shall provide that, without the prior consent in writing by Huaren, such persons shall not be allowed to operate the business the same as or similar to the industry that Huaren and its clients or suppliers engage in, or other industries that are in competition with Huaren, or hold any equity interests of the entities mentioned hereinabove, unless the business or equity holding is via Huaren.
|
Article 10
|
General Representations and Warranties by Transferors
|
The Transferors are PRC citizens with all civil abilities to enter into this Contract and fulfill all of their obligations stipulated herein. Signing this Contract and fulfilling all of their obligations stipulated herein by the Transferors shall not contravene or result in the violation of or constitute a failure to fulfill or an inability to fulfill any of the stipulations in any laws, regulations, stipulations, any authorization or approval from any government body or department or the stipulations of any contract or agreement that any of the Transferors is a Party to or is bound by.
|
Article 11
|
Ownership
|
11.1 The Transferors are the legal owners of the Transferred Shares and have full authority and right to transfer the Transferred Shares to Transferee.
11.2 Transferors hereby jointly undertake and warrant up to and including the Payment Date that the Transferred Shares are not subject to any Claims or Encumbrances (including but not limited to any form of option, acquisition right, mortgage, pledge, guarantee, lien or any other form of Third Party rights).
11.3 No lawsuits, arbitrations, or other legal or administrative proceedings or governmental investigations are on-going against any of Transferors that will materially affect its ability to sign this Contract or fulfill its obligations under this Contract.
|
Article 12
|
Special Representations and Warranties by the Transferors
|
The Transferors hereby specially represent and warrant to the Transferee that:
12.1 Huaren is a legal entity that has been duly incorporated in accordance with PRC laws and it is validly and legally in existence and also operating normally pursuant to PRC laws and regulations. The registered capital of Huaren has been fully paid and is free of any false capital contribution, overrated capital contribution and flight of capital contribution.
12.2 The Transferors hereby jointly warrant that Huaren legally and effectively owns the land use right, plants, machinery equipments and other properties currently occupied. The Transferors warrant that they will take any and all measures to guarantee Huaren legally obtains the right to use all land and obtain the ownership of all buildings with any right encumbrances, which shall not be subject to time and shall remain effective after the Closing Date. The Transferors shall assume the joint and several liabilities in case of any losses suffered by Huaren or the Transferee or any administrative penalties imposed by the governmental authorities due to any causes mentioned hereinabove after the share transfer under this Contact and indemnify the transferee for all losses arisen thereto.
12.3 There has not been and is not any investigation, prosecution, dispute, claim or other proceeding (whether current, pending or threatened) in respect of Huaren, nor Huaren has been punished or Transferors can foresee any punishment to be made by any administrative authorities of the PRC before the share transfer under this Contract, except for those disclosed to the Transferee prior to the Signing Date. The Transferors have fully disclosed all information of Huaren to the Transferee prior to the Signing Date. The Transferors hereby warrant that all tax, fees, charges, penalties and expenses payable to or required to pay to any PRC governmental authority have been fully paid. By the Signing Date, there has been no default in the payment of such tax, fees, charges, penalties and expenses, or any payable cost and/or expenses incurred by the correction of the default and/or inexpedient acts of Huaren required by any governmental authority. The Transferors shall assume the joint and several liabilities in case of any losses, damages or any penalties suffered by Huaren and/or the Transferee due to any investigation, prosecutions, disputes, claims or other proceedings prior to the share transfer under this Contract and shall fully indemnify the Transferee all losses arisen thereto.
12.4 The Transferors hereby warrant that Huaren has obtained all approvals, permissions, consents and fillings necessary to the production and business operation (including but not limited to Pharmaceutical Manufacturing Permit, Good Manufacturing Practices (GMP) Certificate, etc) which are all valid and legal, carried out businesses as stated in their business licenses, and executed contracts and documents with legally binding effects. The Transferors shall assume the joint and several liabilities in case of any losses, damages or any penalties suffered by Huaren or the Transferee due to any absence of the above-mentioned approvals, permissions, consents and fillings prior to the share transfer under this Contract and shall fully indemnify the Transferee all losses arisen thereto.
12.5 The Transferors hereby confirm and warrant that the production, operation and business of Huaren are in full compliance with the relevant PRC laws and regulations. The Transferors shall indemnify and hold the Transferee and Huaren harmless against and from any losses or damages caused by any administrative penalties thereto prior to the Signing Date.
12.6 The Transferors hereby confirm and warrant that the Transferors shall assume jointly and severally liabilities of Huaren to Huaren in order to hold the Transferee harmless for any undisclosed debts and the outstanding interest payable hereto.
12.7 The Transferors hereby irrevocably confirm and warrant that the Transferee shall have right to appoint the financial staffs to Huaren as of the Signing Date and all fiscal expenditure of Huaren shall be made upon the mutual consent in writing jointly by the financial staffs appointed by the Transferee and the financial staffs of the Transferors from the Signing Date to the Payment Date. The financial staffs of the Transferors will withdraw from Huaren and hand over all financial materials to financial staffs appointed by the Transferee for their sole control on the Payment Date.
12.8 The Transferors hereby confirm and warrant that they will ensure the normal operation and management of Huaren prior to the Payment Date and the operation, business and conditions of Huaren will be free of any material adverse change.
12.9 The Transferors hereby irrevocably represent and warrant that Huaren has not made any equity investment on any other companies or entities by the Payment Date. The Transferors shall assume the joint and several liabilities in case of any losses or damages suffered by Huaren or the Transferee in respect of the undisclosed equity investment (if any) and shall fully indemnify the Transferee all losses arisen thereto.
12.10 The Transferors hereby irrevocably represent and warrant that Huaren has not provided security (including but not limited to mortgage, pledge and guarantee) to any other companies, enterprises, entities or natural persons. The Transferors shall assume the joint and several liabilities in case of any losses or damages suffered by Huaren or/and the Transferee due to the undisclosed security and shall indemnify the Transferee all losses arisen thereto.
12.11 Prior to the Signing Date, Transferors have entirely disclosed all information regarding the debts assumed by Huaren. As of the Payment Date, such information remains complete, authentic, accurate and true.
12.12 The Transferors hereby confirm and warrant that Huaren has paid up all taxes required by PRC laws and regulations prior to the Payment Date. The Transferors shall assume the joint and several liabilities for any unpaid taxes of Huaren in order to hold harmless the Transferee against and from any loss and damages arisen thereto.
12.13 The Transferors hereby confirm and warrant that Huaren has obtained the necessary approvals for all of its production and construction projects (no matter whether the project is completed or under construction) from and registrations with relevant PRC governmental authorities, including, but not limited to, environmental impact assessment approvals and the completion acceptance approvals issued by the local environmental protection authority. The Transferors shall be jointly and severally liable to fully indemnify the Transferee in case of any administrative penalty suffered by Huaren arising from hereto due to aforesaid issues (disclosed or undisclosed) after the shares transfer of this Contract.
12.14 The Transferors hereby irrevocably confirm and warrant that the craftwork and technology Huaren adopts currently and the intellectual property owned by it prior to the Payment Date, including but not limited to trademarks, patents and know-how, are in full compliance with relevant PRC laws, regulations, standards or criterion, and free of any infringement of trademarks, patents and know-how of any Third Party. The Transferors shall be jointly and severally liable to fully indemnify the Transferee in case of any penalty, damages or losses suffered by Huaren arisen from such infringement.
12.15 The Transferors hereby irrevocably confirm and warrant that Huaren will obtain environmental impact assessment approvals and completion approvals issued by local environmental protection authority regarding the production and construction projects owned by Huaren within two (2) months from the Closing Date.
12.16 The Transferors hereby irrevocably confirm and warrant that Huaren legally holds Approval Numbers and prior to the Closing Date, Huaren has conducted related procedures of Approval Numbers whose original certificates are lost and required to be registered with relevant authorities and Re-registration Approval Numbers, and Huaren will obtain the certificates of such Approval Numbers and/or Re-registration Approval Numbers within two (2) months from the Signing Date. Any fees arising from the said procedures shall be borne by the Transferors.
12.17 The Transferors hereby irrevocably confirm and warrant that Huaren has signed labor contracts with all of its employees and paid all social insurances, including pension, unemployment insurance, occupational injury insurance, medical insurance maturity insurance and housing funds; the Transferors hereby further confirm and warrant that they shall be jointly and severally liable to fully indemnify the Transferee in case of any penalty, damages or losses suffered by Huaren and/or the Transferee in case Huaren fails to fulfill aforesaid obligations.
12.18 The Transferors hereby irrevocably confirm and warrant that all debts arising prior to the Closing Date shall be borne by the Transferors. The Transferors shall be jointly and severally liable to fully indemnify the Transferee in case of any penalty, damage or loss suffered by Huaren and/or the Transferee arisen from such debts.
12.19 The Transferee is entitled to require the Transferors to undertake the joint and several liabilities and indemnify and hold harmless the Transferee against and from any direct and indirect losses or damages in case of any infringement of any representations and warranties stated hereinabove by the Transferors, or in case that the Transferors fails to meet any or all Pre-requisite Conditions set out in Appendix II attached hereto.
Chapter V Disclosures, Representations and Warranties of Transferee
|
Article 13
|
Disclosures, Representations and Warranties of the Transferee
|
The Transferee hereby represents and warrants to the Transferors that：
13.1 The Transferee is a legal entity that has been duly incorporated, and is validly and legally in existence and also operating normally in accordance with the PRC laws.
13.2 The execution and performance of this Contract by the Transferee will not contravene or result in the violation of or constitute a failure to fulfill or an inability to fulfill any of the stipulations of the Transferee’s articles of association or its internal rules, any laws, regulations, stipulations, or any authorizations or approvals from any government body or department or any contract or agreement that the Transferee is a Party to or is bound by.
13.3 No lawsuits, arbitrations, or other legal or administrative proceedings or governmental investigations are on-going against the Transferee that will materially affect its ability to sign this Contract or fulfill its obligations under this Contract.
Chapter VI Employees
|
Article 14
|
Employees
|
Upon the completion of the share transfer under this Contract, all current employees of Huaren shall continue to be employed. The terms and conditions of their employment including their remuneration for their employment will be implemented in accordance with the stipulations of the labor laws and regulations. Thereafter, Board will determine the staff numbers and working rules, etc., in consideration of business needs.
Chapter VII Confidentiality
|
Article 15
|
Confidentiality
|
15.1 All Parties agree, unless otherwise provided for in another relevant confidentiality agreement, that with regard to the confidential and exclusive information that have been disclosed to or may be disclosed to the other Parties by any Party to this Contract pertaining to their respective businesses, or financial situations and other confidential matters, all Parties to this Contract which have received the aforesaid confidential information (including written information and non-written information, hereinafter referred to as “Confidential Information”) shall:
15.1.1 Keep the aforesaid Confidential Information confidential;
15.1.2 Save for the disclosure of the Confidential Information by a Party to this Contract to its employees solely for the performance of their duties and responsibilities, neither Party to this Contract shall disclose the Confidential Information to any Third Party or any entity.
15.2 The provisions of the aforesaid Article 15.1 shall not apply to Confidential Information:
15.2.1 which was available to the receiving Party from the written record before the disclosing Party disclosed the information to the receiving Party and the written record can prove that the confidential information was already known to the receiving Party;
15.2.2 which has become public information by means not attributable to any breach by the receiving Party;
15.2.3 which was obtained, by the receiving Party from a Third Party not subject to any confidentiality obligation affecting the said Confidential Information.
Chapter VIII Breach of Contract
|
Article 16
|
Liabilities for Violation of Representations or Warranties
|
16.1 If any representation or warranty made by any Party to this Contract is found to be an error, or if any fact that has or is likely to have a major or substantial effect on the signing of this Contract by any Party has been omitted, or if any representation or warranty is found to be misleading or untrue in any material respect, the non-breaching Party shall be entitled to look to the Party (ies) in breach for full compensation for any loss, damage, cost or expense (including any attorneys’ fee and litigation and arbitration fee) arising from the erroneous, misleading or untrue representation or warranty of the Party (ies) in breach or arising from any other breach of any representation and warranty given by the Party (ies) in breach.
16.2 Each representation and warranty set out in this Contract is to be construed independently.
16.3 For the avoidance of doubt, the Transferors hereby unconditionally and irrevocably agree and confirm that they shall be jointly liable for any liability for any breach of representation or warranty.
|
Article 17
|
Liabilities for Breach of Contract
|
17.1 In the event of a breach committed by any Party to this Contract, the said defaulting Party shall be liable to the other Party (ies) for any liabilities arising out of that defaulting Party’s breach of contract in accordance with the provisions of this Contract and the laws and regulations of PRC. In case of breach of Contract by all Parties hereto, a Party shall respectively assume liabilities for any loss or damage, or any other liabilities, arising out of its breach of Contract, against other Parties.
17.2 In the event that Huaren fails to complete the share transfer registration with AIC in accordance with Article 4.4, or the Transferors fail to meet any Pre-requisite Conditions set out in Appendix II or violates any representation, warranty or obligations under this Contract, without account of the intention or gross negligence of the Transferee, Transferors shall pay RMB 1,000,000 to the Transferee, in addition to the compensation for any direct or indirect loss arising therefrom.
Chapter IX Force Majeure
|
Article 18
|
Force Majeure
|
18.1 The Force Majeure shall include earthquake, typhoon, flood, fire, war, political unrest and such special incidents or events that are deemed to be Force Majeure occurrences under the provisions of the relevant laws and regulations of PRC.
18.2 In the event of the occurrence of a Force Majeure event, the obligations of the Party to
this Contract affected by this Force Majeure event shall cease during the period of the Force Majeure event and any term or period set out in this Contract and to which the affected Party is subject shall automatically be extended by a period equal to the term or period of the Force Majeure event, the period of extension shall be the same as the period of cessation of the obligations by reason of the Force Majeure event, and the said Party shall not be liable for any liabilities arising out of a breach of contract as provided for in this Contract for the duration of the Force Majeure.
18.3 The Party claiming the occurrence of a Force Majeure event shall promptly inform the
other Party (ies) in writing, and within seven (7) days thereafter, it shall provide sufficient evidence (issued by the notary organization) of the occurrence and the continuity of the Force Majeure event. It shall also do its best to eliminate the adverse effect of the Force Majeure event.
Chapter X Resolution of Disputes
|
Article 19
|
Arbitration
|
Any dispute arising out of this Contract between the Parties to this Contract shall firstly be resolved through friendly consultation. In case no settlement can be reached through consultation, either Party shall have the right to submit such dispute to China International Economic and Trade Arbitration Commission in Beijing for arbitration in accordance with then effective arbitration rules. The Place of arbitration is Beijing.
|
Article 20
|
Validity of Arbitral Award
|
The arbitration award shall be final and shall be binding on all Parties to this Contract. All Parties to this Contract agree to be bound by the said award, and to act according to the terms of the said award.
|
Article 21
|
Continuation of Rights and Obligations
|
After a dispute has arisen and during its arbitration process, other than the disputed matter, all Parties to this Contract shall continue to exercise their other respective rights stipulated in this Contract, and shall also continue to perform their other respective obligations stipulated in this Contract.
Chapter XI Applicable Law
|
Article 22
|
Applicable Law
|
The laws and regulations of the PRC shall govern and be binding on the establishment, validity, interpretation and execution of this Contract. All disputes arising out of this Contract shall be determined according to the laws of the PRC. In the event that the laws of the PRC do not make provision for a certain issue relating to this Contract, reference shall be made to general international business practice.
Chapter XII Miscellaneous
|
Article 23
|
Non-Waiver
|
The non-exercise or delay in the exercise of an entitlement stipulated in this Contract by any Party to this Contract shall not be regarded as a waiver of the said entitlement. Any single exercise or partial exercise of an entitlement shall not rule out any future re-exercise of the said entitlement.
|
Article 24
|
Transfer
|
Unless otherwise described and prescribed in this Contract, neither Party to this Contract shall transfer or assign all or any part of this Contract or transfer or assign that Party’s entitlement or obligations as stipulated in this Contract.
|
Article 25
|
Amendment
|
25.1 This Contract has been executed for the benefit of all Parties to this Contract and their respective lawful successor(s) and assignees, and shall have legal binding effect on them.
25.2 Any amendment to this Contract shall be made by the Parties in writing. The amendment duly executed by the Parties shall be deemed an integral part of this Contract and shall have the same legal effect as this Contract.
|
Article 26
|
Severability
|
The invalidity of any term in this Contract shall not affect the validity of the other terms in this Contract.
|
Article 27
|
Language
|
This Contract is written in Chinese and English. In case of any inconsistency, the Chinese version shall prevail.
|
Article 28
|
Effectiveness of Text and Appendixes
|
28.1 The Contract shall be effective from the execution of Parties hereof (“Effective Date”). The Contract shall be written in twelve (12) original sets in Chinese, with the Transferors holding seven (7) original sets, the Transferee holding one (1) original set, the AIC holding one (1) original set, and the remaining shall be kept by Huaren and the Transferee.
28.2 The Appendix to this Contract shall form an integral part of this Contract, and shall have the same effect as this Contract
|
Article 29
|
Notification
|
29.1 Unless otherwise specified and prescribed, any Party issuing any notification or written communication to the other Party (ies) according to the provisions of this Contract shall have them written in Chinese and shall send them as a letter by a courier service company, or by facsimile. Letters sent by a courier service company, will require a confirmation to be given seven (7) working days after handing over the notification or communication to the courier service company. Any notification or written communication sent in accordance with the stipulations of this Contract shall be deemed to be effective on the date of receipt. If they are sent by facsimile, the date of receipt shall be deemed to be three (3) working days after transmission, subject to a facsimile confirmation report evidencing this.
29.2 All notices or communications shall be sent to the following addresses, unless and until any such address is changed by written notice to the other Party:
Address of the Transferee：▇▇.▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Postcode: 712046
Tel: (▇▇▇) ▇▇▇▇▇▇▇▇
Fax Number: (▇▇▇) ▇▇▇▇▇▇▇▇
To：▇▇▇▇▇▇ ▇▇▇▇
Address of the Transferors：▇▇.▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Postcode: 714000
Tel: (▇▇▇▇) ▇▇▇▇▇▇▇
Fax Number: (▇▇▇▇) ▇▇▇▇▇▇▇
To: Jian’▇▇▇ ▇▇▇
|
Article 30
|
Entire Agreement
|
This Contract constitutes the entire agreement of all Parties to this Contract pertaining to the transaction agreed upon in this Contract, and shall replace all the previous discussions, negotiations and agreements among all Parties to this Contract in respect of the transaction of this Contract.
The remainder of this page is intentionally left blank）
IN WITNESS WHEREOF, the duly authorized representative of Party A and Party B have signed this Contract on the date first above written.
Party A：Shaanxi Aoxing Pharmaceuticals Co., Ltd.
(Seal)
Authorized Representative(Signature)：
Party B：Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd.
Signature：
Appendix I Shareholders of Huaren
|
1.
|
Jian’▇▇▇ ▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 30% equity interests of Huaren；
|
|
2.
|
▇▇▇ ▇▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 21% equity interests of Huaren；
|
|
3.
|
▇▇▇▇▇▇ ▇▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 10% equity interests of Huaren；
|
|
4.
|
▇▇▇▇▇ ▇▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 10% equity interests of Huaren；
|
|
5.
|
▇▇▇▇ ▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 10% equity interests of Huaren；
|
|
6.
|
▇▇▇▇ ▇▇▇，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 9.5% equity interests of Huaren；
|
|
7.
|
Biao Ning，ID number ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇，holds 9.5% equity interests of Huaren
|
Appendix II Pre-requisite Conditions
Pre-requisite Conditions
Transferors hereby irrevocably guarantee to fulfill all following conditions precedent within the time limit on their own costs:
|
(A)
|
The audited revenues of Huaren in the years of 2009 and 2010 shall be greater than ▇▇▇ ▇▇ million and 28 million respectively and the after tax net margin shall reach 15%. The said auditor refers to the auditor appointed by the Transferee.
|
|
(B)
|
Transferors and Huaren complete the share transfer registration with the local AIC, and the shareholders of Huaren as registered with the AIC have been changed to the Transferee.
|
Appendix III Drug and Health Product Approval Numbers
Drug Approval Numbers
|
Serial Number
|
Drug Number
|
Approval Number
|
|
1
|
Piracetam Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054933
|
|
2
|
Bifendate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054933
|
|
3
|
Paracetamol,Caffein ,Atificial Cow-bezoar and Chlorphenamine Maleate Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H20054935
|
|
4
|
Procaine Hydrochloride Injection
|
▇▇▇ ▇▇▇ Zhun Zi H20054936
|
|
5
|
Nicorandil Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054937
|
|
6
|
Cystine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054938
|
|
7
|
Anticoagulation Solution
|
▇▇▇ ▇▇▇ Zhun Zi H20054939
|
|
8
|
Chlobamolie Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054940
|
|
9
|
Berberine Hydrochloride and Trimethoprim Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054941
|
|
10
|
Compound Reserpine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054942
|
|
11
|
Aspirin Enteric-coated Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054943
|
|
12
|
Aspirin Enteric-coated Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054944
|
|
13
|
Propafenone Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054945
|
|
14
|
Erythromycin Estolate Granule
|
▇▇▇ ▇▇▇ Zhun Zi H20054946
|
|
15
|
Erythromycin Estolate Granule
|
▇▇▇ ▇▇▇ Zhun Zi H20054947
|
|
16
|
Erythromycin Estolate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
17
|
Alginic Sodium Diester Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054949
|
|
18
|
Isosorbide Dinitrate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054950
|
|
19
|
Ranitidine Hydrochloride Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H20054951
|
|
20
|
Propafenone Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054952
|
|
21
|
Propafenone Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054953
|
|
22
|
Tetracycline Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054954
|
|
23
|
Tetracycline Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
24
|
Ethambutol Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054956
|
|
25
|
Pyritinol Hyorochloride Tabelet
|
▇▇▇ ▇▇▇ Zhun Zi H20054957
|
|
26
|
Glucurolactone Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054958
|
|
27
|
Tabellae Acidi Oleanolici
|
▇▇▇ ▇▇▇ Zhun Zi H20054959
|
|
28
|
Tabellae Acidi Oleanolici
|
▇▇▇ ▇▇▇ Zhun Zi H20054960
|
|
29
|
Compound Aminopyrine Phenacetin Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054961
|
|
▇▇
|
▇▇▇▇▇▇▇ ▇ ▇▇▇▇▇▇
|
▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇
|
|
▇▇
|
▇▇▇▇▇▇▇ ▇ ▇▇▇▇▇▇
|
▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇
|
|
▇▇
|
▇▇▇▇▇▇▇ ▇ ▇▇▇▇▇▇
|
▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇
|
|
33
|
Cimetidine Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H20054965
|
|
34
|
Cimetidine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054966
|
|
35
|
Carbamazepine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054967
|
|
36
|
Rifampicin Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H20054968
|
|
37
|
Rifampicin Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H20054969
|
|
38
|
Rifampicin Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054970
|
|
39
|
Sulfamethoxazole,Sulfadiazine and Trimethoprim Tablet
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
40
|
Benproperine Phosphate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054972
|
|
41
|
Chloramphenicol Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054973
|
|
42
|
Aminophylline Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054974
|
|
43
|
Aminophylline Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054974
|
|
44
|
Metamizole Sodium Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054976
|
|
45
|
Metamizole Sodium Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054977
|
|
46
|
Paracetamol Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054978
|
|
47
|
Pipemidic acid Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054979
|
|
48
|
Pipemidic acid Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054980
|
|
49
|
Paracetamol Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054981
|
|
50
|
Paracetamol Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054982
|
|
51
|
Compound Aspirin Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054983
|
|
52
|
Compound Paracetamol Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054984
|
|
53
|
Erythromycin Enteric-coated Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054985
|
|
54
|
Erythromycin Enteric-coated Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054986
|
|
55
|
Sulfadiazine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054987
|
|
56
|
Sulfamidine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054988
|
|
57
|
Inosine Tablets
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
58
|
Inosine Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054993
|
|
59
|
Metronidazole Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20054994
|
|
60
|
Trimethoprim Tablet
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
61
|
Fosfomycin Calcium Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H20054998
|
|
62
|
Tabellae Antipyrini Et Caffeini Citratis
|
▇▇▇ ▇▇▇ Zhun Zi H20054999
|
|
63
|
Tolperisone Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055000
|
|
64
|
Tolperisone Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055001
|
|
65
|
Tolperisone Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
66
|
Erythronycin Stearate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055003
|
|
67
|
Erythronycin Stearate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055004
|
|
68
|
Erythronycin Stearate Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055005
|
|
69
|
Aspirin Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055006
|
|
70
|
Aspirin Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055007
|
|
71
|
Aspirin Enteric-coated Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055008
|
|
72
|
Tetracycline Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055009
|
|
73
|
Tetracycline Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
74
|
Huangyangning Tablets
|
▇▇▇ ▇▇▇ Zhun Zi Z61020805
|
|
75
|
Longdan Xiegan Pill
|
▇▇▇ ▇▇▇ Zhun Zi Z61021149
|
|
76
|
Norfloxacin Capsule
|
▇▇▇ ▇▇▇ Zhun Zi H61021705
|
|
77
|
Berberine Hydrochloride Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20055000
|
|
78
|
Fufang Danshen Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z61021148
|
|
79
|
Vitamin C Yinqiao Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z61021150
|
|
80
|
Compound Sulfamethoxazole Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H61021609
|
|
81
|
Huanglian Shangqing Pill
|
▇▇▇ ▇▇▇ Zhun Zi Z61020804
|
|
82
|
Muxiang Shunqi Pill
|
▇▇▇ ▇▇▇ Zhun Zi Z61020806
|
|
▇▇
|
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
|
▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇
|
|
84
|
Jiakangling Capsule
|
▇▇▇ ▇▇▇ Zhun Zi Z20050163
|
|
85
|
▇▇▇▇▇▇▇ ▇▇▇▇▇ Plaster
|
▇▇▇ ▇▇▇ Zhun Zi Z20043369
|
|
86
|
Qianlietong Capsule
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
Health Products Approval Number
|
Serial Number
|
Health Product Name
|
Approval Name
|
|
1
|
Huaren Changweitong Capsule
|
Guo ▇▇▇ ▇▇▇▇ Zi G20040342
|
Appendix IV Drug Approval Numbers for Re-registration Application
|
Serial Number
|
Drug Name
|
Approval Number
|
|
1
|
Jin’gang Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z20053915
|
|
2
|
Danxiang Rhinitis Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z20063984
|
|
3
|
Azithromycin Dispersible Tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20063547
|
|
4
|
Fuke Zhidai Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z20063475
|
|
5
|
Chuzhangze Haifu Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z20063355
|
|
6
|
Erlong Zuoci Pill
|
▇▇▇ ▇▇▇ Zhun Zi Z20063331
|
|
7
|
Erlong Tongqiao Pill
|
▇▇▇ ▇▇▇ Zhun Zi Z20064318
|
|
8
|
Vitligo Capsule
|
▇▇▇ ▇▇▇ Zhun Zi Z20044243
|
|
9
|
Sifangwei Capsule
|
▇▇▇ ▇▇▇ Zhun Zi Z20063171
|
|
10
|
Yanlixiao Capsule
|
▇▇▇ ▇▇▇ Zhun Zi ▇▇▇▇▇▇▇▇▇
|
|
11
|
Liganlong Capsule
|
▇▇▇ ▇▇▇ Zhun Zi Z20063532
|
|
12
|
Nuan’gong Yunzi Capsule
|
▇▇▇ ▇▇▇ Zhun Zi Z20083379
|
|
13
|
Peikun Capsule
|
▇▇▇ ▇▇▇ Zhun Zi Z20093710
|
Appendix III
Reregistered Drug Approval Numbers
|
Serial Number
|
Drug Name
|
Approval Number
|
|
1
|
King kong Tablet
|
▇▇▇ ▇▇▇ Zhun Zi Z20053915
|
|
2
|
Vitiligo capsule
|
▇▇▇ ▇▇▇ Zhun ZiZ20044243
|
|
3
|
Danxiangrhinitis Tablets
|
▇▇▇ ▇▇▇ Zhun ZiZ20063984
|
|
4
|
Azithromycin dispersible tablet
|
▇▇▇ ▇▇▇ Zhun Zi H20063547
|
|
5
|
Gynecological leucorrhea tablet
|
▇▇▇ ▇▇▇ Zhun ZiZ20063475
|
|
6
|
▇▇▇ ▇▇▇▇▇ ze Haipu tablets
|
▇▇▇ ▇▇▇ Zhun ZiZ20063355
|
|
7
|
Antideaf otic pill
|
▇▇▇ ▇▇▇ Zhun ZiZ20063331
|
|
8
|
Deafness Tongqiao pills
|
▇▇▇ ▇▇▇ Zhun ZiZ20064318
|
|
9
|
Warm palace pregnant son pill
|
▇▇▇ ▇▇▇ Zhun ZiZ20083379
|
|
10
|
Peikun pill
|
▇▇▇ ▇▇▇ Zhun ZiZ20093710
|
|
11
|
Four square stomach capsule
|
▇▇▇ ▇▇▇ Zhun ZiZ20063171
|
|
12
|
Quick-acting anti-inflammation capsule
|
▇▇▇ ▇▇▇ Zhun ZiZ20063139
|
|
13
|
Legalon capsule
|
▇▇▇ ▇▇▇ Zhun ZiZ20063532
|